Literature DB >> 23708586

Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10.

Tobias Eggert1, Katherine A McGlynn, Austin Duffy, Michael Peter Manns, Tim F Greten, Sean F Altekruse.   

Abstract

Entities:  

Keywords:  Hepatocellular CARCINOMA

Mesh：

Substances：

Year:  2013        PMID： 23708586      PMCID： PMC4145809          DOI： 10.1136/gutjnl-2013-305164

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  7 in total

1.  Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.

Authors:  Silvia Tremosini; Alejandro Forner; Loreto Boix; Ramon Vilana; Luis Bianchi; Maria Reig; Jordi Rimola; Carlos Rodríguez-Lope; Carmen Ayuso; Manel Solé; Jordi Bruix
Journal:  Gut       Date:  2012-01-27       Impact factor: 23.059

2.  Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis.

Authors:  Sanjay Kakar; Lawrence J Burgart; Kenneth P Batts; Joaquin Garcia; Dhanpat Jain; Linda D Ferrell
Journal:  Mod Pathol       Date:  2005-11       Impact factor: 7.842

Review 3.  Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants.

Authors:  Kunio Okuda
Journal:  J Gastroenterol Hepatol       Date:  2002-04       Impact factor: 4.029

4.  Fibrolamellar hepatoma.

Authors:  D M Nagorney; M A Adson; L H Weiland; C D Knight; S R Smalley; A R Zinsmeister
Journal:  Am J Surg       Date:  1985-01       Impact factor: 2.565

5.  Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features.

Authors:  J R Craig; R L Peters; H A Edmondson; M Omata
Journal:  Cancer       Date:  1980-07-15       Impact factor: 6.860

6.  Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study.

Authors:  Hashem B El-Serag; Jessica A Davila
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  7 in total
  31 in total

1.  Comments on "JAMA PATIENT PAGE. Treatment of Liver Cancer".

Authors:  Chengpei Zhu; Qinjuan Qian; Xiangchao Meng; Haitao Zhao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Mohamed Shama; Ibrahim Halil Sahin; Ajay Nooka; Hesham M Hassabo; Jean-Nicolas Vauthey; Thomas Aloia; James L Abbruzzese; Ishwaria M Subbiah; Filip Janku; Steven Curley; Manal M Hassan
Journal:  Oncology       Date:  2013-09-19       Impact factor: 2.935

3.  mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma.

Authors:  Kimberly J Riehle; Matthew M Yeh; Jeannette J Yu; Heidi L Kenerson; William P Harris; James O Park; Raymond S Yeung
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

4.  Intracranial metastasis in fibrolamellar hepatocellular carcinoma.

Authors:  William J Hammond; Gadi Lalazar; James A Saltsman; Benjamin A Farber; Enrico Danzer; Tshering C Sherpa; Charles D Banda; Jeffrey R Andolina; Sasan Karimi; Cameron W Brennan; Michael S Torbenson; Michael P La Quaglia; Sanford M Simon
Journal:  Pediatr Blood Cancer       Date:  2017-12-29       Impact factor: 3.167

5.  Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Basile Njei; Venkata Rajesh Konjeti; Ivo Ditah
Journal:  Gastrointest Cancer Res       Date:  2014-03

6.  Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective.

Authors:  Skye C Mayo; Michael N Mavros; Hari Nathan; David Cosgrove; Joseph M Herman; Ihab Kamel; Robert A Anders; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-10-24       Impact factor: 6.113

7.  Structures of the PKA RIα Holoenzyme with the FLHCC Driver J-PKAcα or Wild-Type PKAcα.

Authors:  Baohua Cao; Tsan-Wen Lu; Juliana A Martinez Fiesco; Michael Tomasini; Lixin Fan; Sanford M Simon; Susan S Taylor; Ping Zhang
Journal:  Structure       Date:  2019-03-21       Impact factor: 5.006

8.  Genetic variations in the one-carbon metabolism pathway genes and susceptibility to hepatocellular carcinoma risk: a case-control study.

Authors:  Heng Zhang; Chunhe Liu; Yu-Chen Han; Zuohong Ma; Haiyan Zhang; Yinan Ma; Xiaofang Liu
Journal:  Tumour Biol       Date:  2014-10-16

Review 9.  Precision oncology in liver cancer.

Authors:  Kevin M Sullivan; Heidi L Kenerson; Venu G Pillarisetty; Kimberly J Riehle; Raymond S Yeung
Journal:  Ann Transl Med       Date:  2018-07

Review 10.  Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.

Authors:  Gadi Lalazar; Sanford M Simon
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.